CircSCMH1 Accelerates Sorafenib Resistance in Hepatocellular Carcinoma by Regulating HN1 Expression via miR-485-5p.

已完结 10 由诗奕发布于 2024/11/27 16:56:40

DOI:10.1007/s12033-024-01054-4
作者：Meixiang Li,?Xionghao Pang,?Haixia Xu,?Liang Xiao
文献类型：期刊论文
补充材料：只需要正文

Springer

Abstract：Sorafenib (SOR) is the first-line chemotherapeutic therapy for hepatocellular carcinoma (HCC) treatment, but SOR resistance is a key factor affecting the therapeutic effect. Emerging studies

应助信息

8小时前

xiechao

f33922d7ac9d11efb66734735aa3bc31.pdf 已采纳

8小时前

Book学术机器人

2024/11/27 16:56:40 未找到该文献，机器人已退出，请等待人工下载

2024/11/27 16:56:40 Book学术AI机器人收到请求，开始寻找文献

2024/11/27 16:56:40 已向机器人发送请求

8小时前

诗奕发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Springer与外载荷非线性粘弹性接触的近似恢复系数